Epeleuton

DRUG2 trials

Sponsors

Afimmune

Conditions

Non Alcoholic Fatty Liver DiseaseSickle Cell Disease

Phase 2

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

CompletedNCT02941549

AfimmuneNon Alcoholic Fatty Liver Disease

Start: 2016-12-20End: 2019-03-04Updated: 2022-10-12

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

CompletedNCT05861453

AfimmuneSickle Cell Disease

Start: 2024-01-10End: 2026-02-11Updated: 2026-05-04

Related Papers

A phase 2 open-label study of epeleuton in patients with sickle cell disease

Blood2025-11-03

A Phase 2, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease

Blood2023-11-024 citations

Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

Journal of the American Heart Association2020-08-1125 citations